Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current prices versus minimum costs of production for CFTR modulators.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Sept 2022

Guo Jonathan, Wang Junzheng, Zhang Jingchun, Fortunak Joseph, Hill Andrew

Abstract excerpt

BACKGROUND: While the clinical benefits of CFTR modulators are clear, their high prices render them inaccessible outside of the world's richest countries. Despite this, there is currently limited evidence regarding global access to these transformative therapies. Therefore, this study aims to estimate the minimum costs of production of CFTR modulators, assuming robust generic competition, and to compare them with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Mutation

Share to Quinolones

Source

Identifiers

PMID: 35440408
DOI: 10.1016/j.jcf.2022.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current prices versus minimum costs of production for CFTR modulators.PMID 35440408Read ↗

Current prices versus minimum costs of production for CFTR modulatorsSemantic proximity Read ↗

Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.Semantic proximity Read ↗

Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.Semantic proximity Read ↗

Estimated global cost of treating COVID-19, HIV, Hepatitis B and Hepatitis C with approved effective oral medicationsSemantic proximity Read ↗

Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical ObesitySemantic proximity Read ↗

CFTR Lifecycle Map-A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations.Semantic proximity Read ↗

Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene TherapiesSemantic proximity Read ↗

How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent ExpirySemantic proximity Read ↗

Shining a light in the black box of orphan drug pricingSemantic proximity Read ↗

Guiding the willingness to pay for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome using a cost-based-plus pricing frameworkSemantic proximity Read ↗

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.Semantic proximity Read ↗

Differences in the cost of manufacturing pharmaceuticals in India for differently regulated markets: A comparative analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.